Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Locally Advanced or Metastatic Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial

NCT06121505 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT06121505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06121505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Locally Advanced or Metastatic Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2024
Completion date
February 28, 2027
Enrollment
114 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung squamous cell carcinoma